发明申请
- 专利标题： P13K ISOFORM SELECTIVE INHIBITORS
- 专利标题（中）： P13K ISOFORM选择性抑制剂
-
申请号： US12999032申请日： 2009-07-07
-
公开(公告)号： US20110130395A1公开(公告)日： 2011-06-02
- 发明人: Congxin Liang , Zhigang Li
- 申请人： Congxin Liang , Zhigang Li
- 国际申请： PCT/US09/03979 WO 20090707
- 主分类号： A61K31/5386
- IPC分类号： A61K31/5386 ; A61P9/00 ; A61P31/12 ; A61P35/00 ; A61P25/00 ; A61P37/00 ; A61P29/00 ; A61P5/00 ; A61P3/00 ; C07D473/00 ; A61K31/5377 ; C07D498/08
摘要：
2-Morpholin-4-yl-9H-purine and 5-Morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, especially those substituted by 6-heteroaryl, are unexpected PI3 kinase isoform selective inhibitors with good drug properties and are useful in treating disorders related to abnormal PI3K activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
公开/授权文献
- US08513221B2 PI3K isoform selective inhibitors 公开/授权日：2013-08-20
信息查询
IPC分类:
